Skip to main content
Erschienen in: Zeitschrift für Pneumologie 6/2021

06.10.2021 | Asthma bronchiale | Pädiatrische Pneumologie

Biologika beim schweren/schwierigen Asthma bronchiale im Kindes- und Jugendalter

verfasst von: Prof. Dr. med. Dr. med. habil. Markus A. Rose, MPH

Erschienen in: Zeitschrift für Pneumologie | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das schwere therapierefraktäre Asthma bronchiale ist auch bei Kindern und Jugendlichen selten, stellt aber den Behandler vor besondere diagnostische und therapeutische Herausforderungen. Zunehmend werden im Rahmen der personalisierten Medizin verschiedene Phänotypen identifiziert, die eine individuelle Strategie erfordern. Mit der Verfügbarkeit von Biologika auch für Kinder und Jugendliche gibt es neue therapeutische Optionen. Diese Übersicht stellt die aktuell für Kinder und Jugendliche verfügbaren Biologika dar und gibt Entscheidungshilfen für ihren Einsatz.
Literatur
1.
Zurück zum Zitat AMWF online (2020) Nationale Versorgungsleitlinie Asthma, 4. Aufl. (Version 1, AWMF-Register-Nr.: nvl-002) AMWF online (2020) Nationale Versorgungsleitlinie Asthma, 4. Aufl. (Version 1, AWMF-Register-Nr.: nvl-002)
2.
Zurück zum Zitat Bel EH, Wenzel SE, Thompson PJ et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371(13):1189–1197 Bel EH, Wenzel SE, Thompson PJ et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371(13):1189–1197
3.
Zurück zum Zitat Berger W, Gupta N, McAlary M et al (2003) Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 91(2):182–188PubMed Berger W, Gupta N, McAlary M et al (2003) Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 91(2):182–188PubMed
4.
Zurück zum Zitat Brodlie M, McKean MC, Moss S et al (2012) The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 97(7):604–609PubMed Brodlie M, McKean MC, Moss S et al (2012) The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 97(7):604–609PubMed
5.
Zurück zum Zitat Busse WW, Morgan WJ, Gergen PJ et al (2011) Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364(11):1005–1015PubMedPubMedCentral Busse WW, Morgan WJ, Gergen PJ et al (2011) Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364(11):1005–1015PubMedPubMedCentral
6.
Zurück zum Zitat Castro M, Corren J, Pavord ID et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496PubMed Castro M, Corren J, Pavord ID et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496PubMed
7.
Zurück zum Zitat Chan R, RuiWen Kuo C, Lipworth B et al (2020) Pragmatic clinical perspective on biologics for severe refractory type 2 asthma. J Allergy Clin Immunol Pract 8(10):3363–3370PubMed Chan R, RuiWen Kuo C, Lipworth B et al (2020) Pragmatic clinical perspective on biologics for severe refractory type 2 asthma. J Allergy Clin Immunol Pract 8(10):3363–3370PubMed
8.
Zurück zum Zitat Chung KF, Wenzel SE, Brozek JL et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2):343–373 Chung KF, Wenzel SE, Brozek JL et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2):343–373
9.
Zurück zum Zitat Deschildre A, Marguet C, Salleron J et al (2013) Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 42(5):1224–1233PubMed Deschildre A, Marguet C, Salleron J et al (2013) Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 42(5):1224–1233PubMed
10.
Zurück zum Zitat Deschildre A, Marguet C, Langlois C et al (2015) Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 46(3):856–859PubMed Deschildre A, Marguet C, Langlois C et al (2015) Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 46(3):856–859PubMed
12.
Zurück zum Zitat Eyerich S, Metz M, Bossios A et al (2020) New biological treatments for asthma and skin allergies. Allergy 75(3):546–560PubMed Eyerich S, Metz M, Bossios A et al (2020) New biological treatments for asthma and skin allergies. Allergy 75(3):546–560PubMed
13.
Zurück zum Zitat Farne HA, Wilson A, Powell C et al (2017) Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 9:CD10834PubMed Farne HA, Wilson A, Powell C et al (2017) Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 9:CD10834PubMed
14.
Zurück zum Zitat Fitzpatrick AM (2016) Severe asthma in children: lessons learned and future directions. J Allergy Clin Immunol Pract 4(1):11–19PubMedPubMedCentral Fitzpatrick AM (2016) Severe asthma in children: lessons learned and future directions. J Allergy Clin Immunol Pract 4(1):11–19PubMedPubMedCentral
15.
Zurück zum Zitat Fleming L, Murray C, Bansal AT et al (2015) The burden of severe asthma in childhood and adolescence: results from the paediatric U‑BIOPRED cohorts. Eur Respir J 46(5):1322–1333PubMed Fleming L, Murray C, Bansal AT et al (2015) The burden of severe asthma in childhood and adolescence: results from the paediatric U‑BIOPRED cohorts. Eur Respir J 46(5):1322–1333PubMed
16.
Zurück zum Zitat Flood-Page P, Swenson C, Faiferman I et al (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176(11):1062–1071PubMed Flood-Page P, Swenson C, Faiferman I et al (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176(11):1062–1071PubMed
17.
Zurück zum Zitat Gupta A, Pouliquen I, Austin D et al (2019) Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol 54(12):1957–1967PubMedPubMedCentral Gupta A, Pouliquen I, Austin D et al (2019) Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol 54(12):1957–1967PubMedPubMedCentral
18.
Zurück zum Zitat Henriksen DP, Bodtger U, Sidenius K et al (2018) Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL‑5 treatments of severe asthma—a systematic review and meta-analysis. Eur Clin Respir J 5(1):1536097PubMedPubMedCentral Henriksen DP, Bodtger U, Sidenius K et al (2018) Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL‑5 treatments of severe asthma—a systematic review and meta-analysis. Eur Clin Respir J 5(1):1536097PubMedPubMedCentral
19.
Zurück zum Zitat Holguin F, Cardet JC, Chung KF et al (2020) Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J 55(1):1900588PubMed Holguin F, Cardet JC, Chung KF et al (2020) Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J 55(1):1900588PubMed
20.
21.
Zurück zum Zitat Licari A, Marseglia G, Castagnoli R et al (2015) The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov 10(9):1033–1042PubMed Licari A, Marseglia G, Castagnoli R et al (2015) The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov 10(9):1033–1042PubMed
22.
Zurück zum Zitat Licari A, Castagnoli R, Denicolo C et al (2017a) Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev 13(1):36–42PubMedPubMedCentral Licari A, Castagnoli R, Denicolo C et al (2017a) Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev 13(1):36–42PubMedPubMedCentral
23.
Zurück zum Zitat Licari A, Castagnoli R, Denicolò CF et al (2017b) The nose and the lung: united airway disease? Front Pediatr 5:44PubMedPubMedCentral Licari A, Castagnoli R, Denicolò CF et al (2017b) The nose and the lung: united airway disease? Front Pediatr 5:44PubMedPubMedCentral
24.
Zurück zum Zitat Licari A, Brambilla I, Marseglia A et al (2018a) Difficult vs. severe asthma: definition and limits of asthma control in the pediatric population. Front Pediatr 6:170PubMedPubMedCentral Licari A, Brambilla I, Marseglia A et al (2018a) Difficult vs. severe asthma: definition and limits of asthma control in the pediatric population. Front Pediatr 6:170PubMedPubMedCentral
25.
Zurück zum Zitat Licari A, Castagnoli R, Brambilla I et al (2018b) Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol 31(2):44–55PubMedPubMedCentral Licari A, Castagnoli R, Brambilla I et al (2018b) Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol 31(2):44–55PubMedPubMedCentral
26.
Zurück zum Zitat Licari A, Manti S, Chiappini E et al (2020) Severe asthma in children: current goals and unmet needs. Pediatr Allergy Immunol 31(24):40–42PubMed Licari A, Manti S, Chiappini E et al (2020) Severe asthma in children: current goals and unmet needs. Pediatr Allergy Immunol 31(24):40–42PubMed
27.
Zurück zum Zitat Long A, Rahmaoui A, Rothman KJ et al (2014) Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 134(3):560–567PubMed Long A, Rahmaoui A, Rothman KJ et al (2014) Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 134(3):560–567PubMed
28.
Zurück zum Zitat Manka LA, Wechsler ME (2018) New biologics for allergic diseases. Expert Rev Clin Immunol 14(4):285–296PubMed Manka LA, Wechsler ME (2018) New biologics for allergic diseases. Expert Rev Clin Immunol 14(4):285–296PubMed
29.
Zurück zum Zitat Manti S, Brown P, Perez MK et al (2017) The role of neurotrophins in inflammation and allergy. Vitam Horm 104:313–341PubMed Manti S, Brown P, Perez MK et al (2017) The role of neurotrophins in inflammation and allergy. Vitam Horm 104:313–341PubMed
30.
Zurück zum Zitat Maspero J, Fitzgerald M, Pavord I et al (2018) Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the liberty asthma quest study. Chest 154(4):25A–27A Maspero J, Fitzgerald M, Pavord I et al (2018) Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the liberty asthma quest study. Chest 154(4):25A–27A
31.
Zurück zum Zitat Miraglia Del Giudice M, Marseglia GL, Leonardi S et al (2011) Fractional exhaled nitric oxide measurements in rhinitis and asthma in children. Int J Immunopathol Pharmacol 24(4):29–32PubMed Miraglia Del Giudice M, Marseglia GL, Leonardi S et al (2011) Fractional exhaled nitric oxide measurements in rhinitis and asthma in children. Int J Immunopathol Pharmacol 24(4):29–32PubMed
32.
Zurück zum Zitat Montalbano L, Ferrante G, Montella S et al (2020) Relationship between quality of life and behavioural disorders in children with persistent asthma: a multiple indicators multiple causes (MIMIC) model. Sci Rep 10(1):6957PubMedPubMedCentral Montalbano L, Ferrante G, Montella S et al (2020) Relationship between quality of life and behavioural disorders in children with persistent asthma: a multiple indicators multiple causes (MIMIC) model. Sci Rep 10(1):6957PubMedPubMedCentral
33.
Zurück zum Zitat Montella S, Baraldi E, Cazzato S et al (2016) Severe asthma features in children: a case-control online survey. Ital J Pediatr 42(1):9PubMedPubMedCentral Montella S, Baraldi E, Cazzato S et al (2016) Severe asthma features in children: a case-control online survey. Ital J Pediatr 42(1):9PubMedPubMedCentral
34.
Zurück zum Zitat Mukherjee M, Nair P (2015) Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med 3(11):824–825PubMed Mukherjee M, Nair P (2015) Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med 3(11):824–825PubMed
36.
Zurück zum Zitat Rabe KF, Nair P, Brusselle G et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475–2485PubMed Rabe KF, Nair P, Brusselle G et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475–2485PubMed
37.
Zurück zum Zitat Ramratnam SK, Bacharier LB, Guilbert TW (2017) Severe asthma in children. J Allergy Clin Immunol Pract 5(4):889–898PubMed Ramratnam SK, Bacharier LB, Guilbert TW (2017) Severe asthma in children. J Allergy Clin Immunol Pract 5(4):889–898PubMed
38.
Zurück zum Zitat Rusconi F, Fernandes RM, Pijnenburg MWH et al (2018) The severe paediatric asthma collaborative in Europe (SPACE) ERS clinical research collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers. Eur Respir J 52(4):1801665PubMed Rusconi F, Fernandes RM, Pijnenburg MWH et al (2018) The severe paediatric asthma collaborative in Europe (SPACE) ERS clinical research collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers. Eur Respir J 52(4):1801665PubMed
42.
Zurück zum Zitat Santini G, Mores N, Malerba M et al (2017) Dupilumab for the treatment of asthma. Expert Opin Investig Drugs 26(3):357–366PubMed Santini G, Mores N, Malerba M et al (2017) Dupilumab for the treatment of asthma. Expert Opin Investig Drugs 26(3):357–366PubMed
43.
Zurück zum Zitat Shepard HM, Phillips GL, Thanos CD, Feldmann M (2017) Developments in therapy with monoclonal antibodies and related proteins. Clin Med 17:220–232 Shepard HM, Phillips GL, Thanos CD, Feldmann M (2017) Developments in therapy with monoclonal antibodies and related proteins. Clin Med 17:220–232
44.
Zurück zum Zitat Sorkness CA, Wildfire JJ, Calatroni A et al (2013) Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract 1(2):163–171PubMedPubMedCentral Sorkness CA, Wildfire JJ, Calatroni A et al (2013) Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract 1(2):163–171PubMedPubMedCentral
45.
Zurück zum Zitat Teach SJ, Gill MA, Togias A et al (2015) Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 136(6):1476–1485PubMedPubMedCentral Teach SJ, Gill MA, Togias A et al (2015) Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 136(6):1476–1485PubMedPubMedCentral
46.
Zurück zum Zitat Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, Marseglia GL (2021) Biological therapies in children and adolescents with severe uncontrolled asthma: a practical review. Biol Targets Ther 15:133–142 Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, Marseglia GL (2021) Biological therapies in children and adolescents with severe uncontrolled asthma: a practical review. Biol Targets Ther 15:133–142
47.
Zurück zum Zitat Wenzel S, Castro M, Corren J et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to high-dose inhaled corticosteroids plus a long-acting β2 agonist: a rando-mised double-blind placebo-controlled pivotal phase 2b doseranging trial. Lancet 388(10039):31–44PubMed Wenzel S, Castro M, Corren J et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to high-dose inhaled corticosteroids plus a long-acting β2 agonist: a rando-mised double-blind placebo-controlled pivotal phase 2b doseranging trial. Lancet 388(10039):31–44PubMed
48.
Zurück zum Zitat Busse W, Buhl R, Fernandez Vidaurre C et al (2012) Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 129(4):983–989PubMed Busse W, Buhl R, Fernandez Vidaurre C et al (2012) Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 129(4):983–989PubMed
49.
Zurück zum Zitat Busse WW, Maspero JF, Rabe KF et al (2018) Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 35(5):737–748PubMedPubMedCentral Busse WW, Maspero JF, Rabe KF et al (2018) Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 35(5):737–748PubMedPubMedCentral
50.
Zurück zum Zitat Chipps BE, Lanier B, Milgrom H et al (2017) Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol 139(5):1431–1444PubMed Chipps BE, Lanier B, Milgrom H et al (2017) Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol 139(5):1431–1444PubMed
51.
Zurück zum Zitat Drick N, Seeliger B, Welte T et al (2018) Anti-IL‑5 therapy in patients with severe eosinophilic asthma-clinical efficacy and possible criteria for treatment response. BMC Pulm Med 18(1):119PubMedPubMedCentral Drick N, Seeliger B, Welte T et al (2018) Anti-IL‑5 therapy in patients with severe eosinophilic asthma-clinical efficacy and possible criteria for treatment response. BMC Pulm Med 18(1):119PubMedPubMedCentral
54.
Zurück zum Zitat Goulet DR, Atkins WM (2020) Considerations for the design of antibody-based therapeutics. J Pharm Sci 109:74–103PubMed Goulet DR, Atkins WM (2020) Considerations for the design of antibody-based therapeutics. J Pharm Sci 109:74–103PubMed
57.
Zurück zum Zitat Lanier B, Bridges T, Kulus M et al (2009) Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124(6):1210–1216PubMed Lanier B, Bridges T, Kulus M et al (2009) Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124(6):1210–1216PubMed
58.
Zurück zum Zitat Licari A, Brambilla I, De Filippo M et al (2017) The role of upper airway pathology as a comorbidity in severe asthma. Expert Rev Respir Med 11(11):855–865PubMed Licari A, Brambilla I, De Filippo M et al (2017) The role of upper airway pathology as a comorbidity in severe asthma. Expert Rev Respir Med 11(11):855–865PubMed
59.
Zurück zum Zitat Licari A, Manti S, Castagnoli R et al (2019) Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs 21(4):215–237PubMed Licari A, Manti S, Castagnoli R et al (2019) Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs 21(4):215–237PubMed
60.
Zurück zum Zitat Little M, Kipriyanov S, Le Gall F, Moldenhauer G (2000) Of mice and men: hybridoma and recombinant antibodies. Immunol Today 21:364–370PubMed Little M, Kipriyanov S, Le Gall F, Moldenhauer G (2000) Of mice and men: hybridoma and recombinant antibodies. Immunol Today 21:364–370PubMed
61.
Zurück zum Zitat Lugogo N, Domingo C, Chanez P et al (2016) Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther 38(9):2058–2070PubMed Lugogo N, Domingo C, Chanez P et al (2016) Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther 38(9):2058–2070PubMed
62.
Zurück zum Zitat Milgrom H, Fowler-Taylor A, Vidaurre CF et al (2011) Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 27(1):163–169PubMed Milgrom H, Fowler-Taylor A, Vidaurre CF et al (2011) Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 27(1):163–169PubMed
63.
Zurück zum Zitat Normansell R, Walker S, Milan SJ et al (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 1:CD3559 Normansell R, Walker S, Milan SJ et al (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 1:CD3559
64.
Zurück zum Zitat Ortega H, Llanos JP, Lafeuille MH et al (2019) Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data. J Asthma 56(8):808–815PubMed Ortega H, Llanos JP, Lafeuille MH et al (2019) Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data. J Asthma 56(8):808–815PubMed
65.
Zurück zum Zitat Ortega HG, Liu MC, Pavord ID et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371(13):1198–1207 Ortega HG, Liu MC, Pavord ID et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371(13):1198–1207
66.
Zurück zum Zitat Pavord ID, Kom S, Howarth P et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842):651–659 Pavord ID, Kom S, Howarth P et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842):651–659
67.
Zurück zum Zitat Pitrez PM, de Souza RG, Roncada C et al (2017) Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: a real-life study. Pediatr Pulmonol 52(11):1408–1413PubMed Pitrez PM, de Souza RG, Roncada C et al (2017) Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: a real-life study. Pediatr Pulmonol 52(11):1408–1413PubMed
68.
Zurück zum Zitat Rodrigo GJ, Neffen H (2015) Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 26(6):551–556PubMed Rodrigo GJ, Neffen H (2015) Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 26(6):551–556PubMed
69.
Zurück zum Zitat Samitas K, Zervas E, Gaga M (2017) T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med 23(1):48–55PubMed Samitas K, Zervas E, Gaga M (2017) T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med 23(1):48–55PubMed
70.
Zurück zum Zitat Sesé L, Schneider M, Bourgoin M et al (2019) Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy 49(5):733PubMed Sesé L, Schneider M, Bourgoin M et al (2019) Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy 49(5):733PubMed
Metadaten
Titel
Biologika beim schweren/schwierigen Asthma bronchiale im Kindes- und Jugendalter
verfasst von
Prof. Dr. med. Dr. med. habil. Markus A. Rose, MPH
Publikationsdatum
06.10.2021
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Pneumologie / Ausgabe 6/2021
Print ISSN: 2731-7404
Elektronische ISSN: 2731-7412
DOI
https://doi.org/10.1007/s10405-021-00414-0

Weitere Artikel der Ausgabe 6/2021

Zeitschrift für Pneumologie 6/2021 Zur Ausgabe

Einführung zum Thema

Allergie in der Pneumologie

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.